NASDAQ:CBAY - CymaBay Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$11.36 -0.89 (-7.27 %)
(As of 05/27/2018 09:56 AM ET)
Previous Close$11.36
Today's Range$11.20 - $12.26
52-Week Range$3.95 - $15.59
Volume787,050 shs
Average Volume598,059 shs
Market Capitalization$667.62 million
P/E RatioN/A
Dividend YieldN/A
Beta2.08

About CymaBay Therapeutics (NASDAQ:CBAY)

CymaBay Therapeutics logoCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops arhalofenate, which has completed five Phase II clinical trials for the treatment of patients with gout; and MBX-2982, an oral G-protein coupled receptor agonist that has completed one Phase II clinical trial for therapeutic indications. It has licensing agreement with Kowa Pharmaceuticals America, Inc. for the development and commercialization of arhalofenate in the United States; and Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders, as well as a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Receive CBAY News and Ratings via Email

Sign-up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CBAY
CUSIPN/A
Phone510-293-8800

Debt

Debt-to-Equity Ratio0.01
Current Ratio12.91
Quick Ratio12.91

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$10 million
Price / Sales66.76
Cash FlowN/A
Price / CashN/A
Book Value$3.61 per share
Price / Book3.15

Profitability

EPS (Most Recent Fiscal Year)($0.79)
Net Income$-27,550,000.00
Net MarginsN/A
Return on Equity-40.66%
Return on Assets-34.13%

Miscellaneous

Employees26
Outstanding Shares58,770,000

CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics (NASDAQ:CBAY) released its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.32) EPS for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.18. View CymaBay Therapeutics' Earnings History.

When is CymaBay Therapeutics' next earnings date?

CymaBay Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for CymaBay Therapeutics.

What price target have analysts set for CBAY?

11 brokerages have issued 12 month price objectives for CymaBay Therapeutics' stock. Their predictions range from $15.00 to $27.00. On average, they expect CymaBay Therapeutics' share price to reach $18.7778 in the next twelve months. View Analyst Ratings for CymaBay Therapeutics.

What are Wall Street analysts saying about CymaBay Therapeutics stock?

Here are some recent quotes from research analysts about CymaBay Therapeutics stock:
  • 1. According to Zacks Investment Research, "CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. " (5/22/2018)
  • 2. HC Wainwright analysts commented, "EASL; Phase 3 Initiation in 2H18 on Track; Affirm Buy Stock Data 03/27/2018 Price $12.00 Exchange NASDAQ Price Target $18.00 52-Week High $15.59 52-Week Low $3.16 Enterprise Value (M) $611.7 Market Cap (M) $702 Public Market Float (M) 19.5 Shares Outstanding (M) 58.5 3 Month Avg Volume 980,454 Short Interest (M) 2.59 Balance Sheet Metrics Cash (M) $97.2 Total Debt (M) $6.9 Total Cash/Share $1.66 Book Value/Share $2.16 Cash (M): Amount shown is as of December 31 and does not include the $135.5M net proceeds from the recent equity raise.. EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.29) (0.20) (0.21) 2Q (0.30) (0.31) (0.22) 3Q (0.25) (0.21) (0.25) 4Q (0.30) (0.11) (0.27) FY (1.14) (0.79) (0.95) Revenue ($M) Full Year – Dec 2016A 2017A 2018E 1Q 0.0 4.8 0.0 2Q 0.0 0.0 0.0 3Q 0.0 0.0 0.0 4Q 0.0 5.2 0.0 FY 0.0 10.0 5.0 20 15 10 5 0 MAR- 17 J UL- 17 NOV- 17 MAR- 18 12 10 8 6 4 2 0 Vol." (3/28/2018)
  • 3. Cantor Fitzgerald analysts commented, "Clarity on Phase 3 PBC trial design should come before end of 2Q18. Management noted that discussions with U.S. and European regulators are ongoing and expressed pleasure with the level of engagement. Once the details have been finalized, the company expects to share them with the Street. High level, the company anticipates conducting a single pivotal study involving a treatment period of 12 months." (3/16/2018)

Who are some of CymaBay Therapeutics' key competitors?

Who are CymaBay Therapeutics' key executives?

CymaBay Therapeutics' management team includes the folowing people:
  • Dr. Robert James Wills, Exec. Chairman (Age 64)
  • Dr. Charles A. McWherter Ph.D., Sr. VP & Chief Scientific Officer (Age 63)
  • Dr. Pol F. Boudes M.D., Ph.D., Chief Medical Officer (Age 61)
  • Mr. Sujal A. Shah, Pres, CEO & Director (Age 45)
  • Mr. Daniel Menold, Principal Financial Officer, Principal Accounting Officer & VP - Fin. (Age 48)

Has CymaBay Therapeutics been receiving favorable news coverage?

Press coverage about CBAY stock has trended somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. CymaBay Therapeutics earned a coverage optimism score of 0.07 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 47.24 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are CymaBay Therapeutics' major shareholders?

CymaBay Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (5.03%), Foresite Capital Management IV LLC (3.59%), Franklin Resources Inc. (3.06%), Foresite Capital Management III LLC (2.66%), BlackRock Inc. (1.99%) and Millennium Management LLC (1.97%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Charles Mcwherter, Kurt Von Emster, Robert James Wills and Sujal Shah. View Institutional Ownership Trends for CymaBay Therapeutics.

Which institutional investors are selling CymaBay Therapeutics stock?

CBAY stock was sold by a variety of institutional investors in the last quarter, including Abingworth LLP, Farallon Capital Management LLC, Foresite Capital Management IV LLC, Barclays PLC, DAFNA Capital Management LLC, Baird Financial Group Inc., Alpine Global Management LLC and California Public Employees Retirement System. Company insiders that have sold CymaBay Therapeutics company stock in the last year include Carl Goldfischer and Kurt Von Emster. View Insider Buying and Selling for CymaBay Therapeutics.

Which institutional investors are buying CymaBay Therapeutics stock?

CBAY stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Foresite Capital Management III LLC, Redmile Group LLC, BlackRock Inc., Artal Group S.A., Citadel Advisors LLC, Franklin Resources Inc. and Nexthera Capital LP. Company insiders that have bought CymaBay Therapeutics stock in the last two years include Charles Mcwherter, Robert James Wills and Sujal Shah. View Insider Buying and Selling for CymaBay Therapeutics.

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $11.36.

How big of a company is CymaBay Therapeutics?

CymaBay Therapeutics has a market capitalization of $667.62 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-27,550,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. CymaBay Therapeutics employs 26 workers across the globe.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7999 GATEWAY BLVD SUITE 130, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected]


MarketBeat Community Rating for CymaBay Therapeutics (CBAY)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  245 (Vote Outperform)
Underperform Votes:  159 (Vote Underperform)
Total Votes:  404
MarketBeat's community ratings are surveys of what our community members think about CymaBay Therapeutics and other stocks. Vote "Outperform" if you believe CBAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBAY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CymaBay Therapeutics (NASDAQ:CBAY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for CymaBay Therapeutics in the last 12 months. Their average twelve-month price target is $18.7778, suggesting that the stock has a possible upside of 65.30%. The high price target for CBAY is $27.00 and the low price target for CBAY is $15.00. There are currently 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.7778$18.7778$16.5556$14.50
Price Target Upside: 65.30% upside43.12% upside35.15% upside68.80% upside

CymaBay Therapeutics (NASDAQ:CBAY) Consensus Price Target History

Price Target History for CymaBay Therapeutics (NASDAQ:CBAY)

CymaBay Therapeutics (NASDAQ:CBAY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018OppenheimerSet Price TargetBuy$20.00HighView Rating Details
4/13/2018HC WainwrightBoost Price TargetBuy$21.00LowView Rating Details
4/11/2018Leerink SwannBoost Price TargetOutperform$16.00 ➝ $20.00HighView Rating Details
3/16/2018SunTrust BanksReiterated RatingBuy$19.00HighView Rating Details
3/16/2018Piper Jaffray CompaniesReiterated RatingBuy$16.00HighView Rating Details
3/16/2018Cantor FitzgeraldReiterated RatingBuy$16.00LowView Rating Details
2/13/2018Evercore ISIInitiated CoverageOutperform ➝ OutperformHighView Rating Details
1/25/2018Roth CapitalReiterated RatingBuy ➝ Buy$27.00HighView Rating Details
8/11/2017Ifs SecuritiesDowngradeStrong-Buy ➝ OutperformHighView Rating Details
7/20/2017CIBCReiterated RatingOutperform ➝ Outperform$8.00 ➝ $15.00MediumView Rating Details
7/20/2017CitigroupReiterated RatingOutperform$8.00 ➝ $15.00MediumView Rating Details
(Data available from 5/27/2016 forward)

Earnings

CymaBay Therapeutics (NASDAQ:CBAY) Earnings History and Estimates Chart

Earnings by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

CymaBay Therapeutics (NASDAQ:CBAY) Earnings Estimates

2018 EPS Consensus Estimate: ($0.94)
2019 EPS Consensus Estimate: ($1.12)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184($0.23)($0.07)($0.17)
Q2 20184($0.25)($0.22)($0.24)
Q3 20184($0.28)($0.23)($0.26)
Q4 20184($0.33)($0.25)($0.28)
Q1 20191($0.26)($0.26)($0.26)
Q2 20191($0.28)($0.28)($0.28)
Q3 20191($0.28)($0.28)($0.28)
Q4 20191($0.30)($0.30)($0.30)

CymaBay Therapeutics (NASDAQ CBAY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2018($0.24)N/AView Earnings Details
5/9/2018Q1 2018($0.14)($0.32)$5.00 millionViewN/AView Earnings Details
3/15/2018Q4 2017($0.17)($0.11)$1.25 million$5.20 millionViewListenView Earnings Details
11/8/2017Q3 2017($0.19)($0.21)$9.50 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.25)($0.31)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.2670)($0.20)$4.79 millionViewN/AView Earnings Details
3/23/2017Q4 2016($0.28)($0.30)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.31)($0.25)ViewListenView Earnings Details
8/9/2016Q2($0.32)($0.30)ViewN/AView Earnings Details
5/11/2016Q1($0.28)($0.29)ViewListenView Earnings Details
3/29/2016Q4($0.35)($0.26)ViewListenView Earnings Details
11/12/2015Q315($0.33)($0.27)ViewListenView Earnings Details
8/10/2015Q215($0.42)($0.09)ViewListenView Earnings Details
5/7/2015Q1 2015($0.43)($0.44)ViewN/AView Earnings Details
3/18/2015Q414($0.46)($0.87)ViewN/AView Earnings Details
11/12/2014Q314($0.48)($0.44)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

CymaBay Therapeutics (NASDAQ:CBAY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

CymaBay Therapeutics (NASDAQ CBAY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.50%
Institutional Ownership Percentage: 82.05%
Insider Trading History for CymaBay Therapeutics (NASDAQ:CBAY)
Institutional Ownership by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

CymaBay Therapeutics (NASDAQ CBAY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/11/2018Sujal ShahCEOBuy5,000$10.65$53,250.0090,000View SEC Filing  
3/22/2018Carl GoldfischerDirectorSell15,000$13.03$195,450.009,340View SEC Filing  
3/5/2018Kurt Von EmsterDirectorSell13,353$15.51$207,105.0390,000View SEC Filing  
2/14/2018Kurt Von EmsterDirectorSell218,057$15.89$3,464,925.73View SEC Filing  
2/7/2018Kurt Von EmsterDirectorSell40,763$12.35$503,423.0590,000View SEC Filing  
2/5/2018Kurt Von EmsterDirectorSell18,831$12.14$228,608.34View SEC Filing  
2/2/2018Kurt Von EmsterDirectorSell90,098$12.15$1,094,690.70View SEC Filing  
1/31/2018Kurt Von EmsterDirectorSell97,639$12.22$1,193,148.5890,000View SEC Filing  
1/25/2018Kurt Von EmsterDirectorSell39,438$12.18$480,354.8490,000View SEC Filing  
1/22/2018Kurt Von EmsterDirectorSell138,253$10.40$1,437,831.2090,000View SEC Filing  
1/19/2018Kurt Von EmsterDirectorSell144,216$10.25$1,478,214.0090,000View SEC Filing  
1/5/2018Kurt Von EmsterDirectorSell4,300$10.21$43,903.0090,000View SEC Filing  
12/22/2017Kurt Von EmsterDirectorSell173,192$9.41$1,629,736.7290,000View SEC Filing  
11/10/2017Kurt Von EmsterDirectorSell50,048$9.26$463,444.4890,000View SEC Filing  
11/2/2017Carl GoldfischerDirectorSell18,000$8.66$155,880.009,000View SEC Filing  
11/2/2017Charles McwherterSVPBuy5,000$8.67$43,350.0010,300View SEC Filing  
10/31/2017Kurt Von EmsterDirectorSell59,209$9.27$548,867.4390,000View SEC Filing  
10/3/2017Kurt Von EmsterDirectorSell108,876$7.85$854,676.60View SEC Filing  
9/29/2017Kurt Von EmsterDirectorSell211,124$8.09$1,707,993.16View SEC Filing  
8/1/2017Robert James WillsDirectorBuy5,000$6.84$34,200.0025,200View SEC Filing  
7/20/2017Charles McwherterSVPBuy5,000$7.43$37,150.005,100View SEC Filing  
7/20/2017Sujal ShahInsiderBuy10,000$7.34$73,400.0075,891View SEC Filing  
9/6/2016Robert James WillsDirectorBuy25,000$2.43$60,750.0025,000View SEC Filing  
4/15/2016Charles McwherterVPBuy3,000$1.68$5,040.005,000View SEC Filing  
4/5/2016Sujal ShahCFOBuy55,000$1.39$76,450.0042,000View SEC Filing  
4/4/2016Sujal ShahCFOBuy22,000$1.39$30,580.0042,000View SEC Filing  
9/11/2015Carl GoldfischerDirectorSell46,729$2.74$128,037.46View SEC Filing  
8/14/2015Emster Kurt VonDirectorBuy90,000$2.69$242,100.00View SEC Filing  
7/20/2015Emster Kurt VonDirectorBuy1,600,000$2.81$4,496,000.00View SEC Filing  
5/18/2015Sujal ShahCFOBuy10,000$3.40$34,000.00View SEC Filing  
5/18/2015Wart Harold VanCEOBuy7,500$3.34$25,050.00View SEC Filing  
5/15/2015Charles McwherterVPBuy2,000$3.16$6,320.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CymaBay Therapeutics (NASDAQ CBAY) News Headlines

Source:
DateHeadline
CymaBay Therapeutics Expected to Earn FY2018 Earnings of ($1.00) Per Share (CBAY)CymaBay Therapeutics Expected to Earn FY2018 Earnings of ($1.00) Per Share (CBAY)
www.americanbankingnews.com - May 24 at 8:36 AM
Zacks: Brokerages Anticipate CymaBay Therapeutics (CBAY) to Announce -$0.24 Earnings Per ShareZacks: Brokerages Anticipate CymaBay Therapeutics (CBAY) to Announce -$0.24 Earnings Per Share
www.americanbankingnews.com - May 20 at 1:16 AM
CymaBay Therapeutics (CBAY) Receives Average Recommendation of "Buy" from AnalystsCymaBay Therapeutics (CBAY) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 16 at 1:24 AM
Insider Buying: CymaBay Therapeutics (CBAY) CEO Acquires 5,000 Shares of StockInsider Buying: CymaBay Therapeutics (CBAY) CEO Acquires 5,000 Shares of Stock
www.americanbankingnews.com - May 15 at 10:29 AM
Edited Transcript of CBAY earnings conference call or presentation 8-May-18 8:30pm GMTEdited Transcript of CBAY earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 12 at 10:31 AM
BidaskClub Lowers CymaBay Therapeutics (CBAY) to HoldBidaskClub Lowers CymaBay Therapeutics (CBAY) to Hold
www.americanbankingnews.com - May 11 at 9:13 PM
Oppenheimer Analysts Lower Earnings Estimates for CymaBay Therapeutics (CBAY)Oppenheimer Analysts Lower Earnings Estimates for CymaBay Therapeutics (CBAY)
www.americanbankingnews.com - May 11 at 9:45 AM
Q2 2018 EPS Estimates for CymaBay Therapeutics (CBAY) Reduced by Leerink SwannQ2 2018 EPS Estimates for CymaBay Therapeutics (CBAY) Reduced by Leerink Swann
www.americanbankingnews.com - May 11 at 9:45 AM
Q2 2018 Earnings Estimate for CymaBay Therapeutics Issued By Piper Jaffray (CBAY)Q2 2018 Earnings Estimate for CymaBay Therapeutics Issued By Piper Jaffray (CBAY)
www.americanbankingnews.com - May 11 at 9:45 AM
CymaBay Therapeutics (CBAY) Given a $20.00 Price Target by Oppenheimer AnalystsCymaBay Therapeutics (CBAY) Given a $20.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - May 9 at 12:08 PM
CymaBay Therapeutics (CBAY) CEO Sujal Shah on Q1 2018 Results - Earnings Call TranscriptCymaBay Therapeutics' (CBAY) CEO Sujal Shah on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 10:08 AM
CymaBay Reports First Quarter 2018 Financial Results and Provides Corporate UpdateCymaBay Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 9 at 10:08 AM
CymaBay Therapeutics (CBAY) Issues  Earnings ResultsCymaBay Therapeutics (CBAY) Issues Earnings Results
www.americanbankingnews.com - May 8 at 10:30 PM
CymaBay Therapeutics (CBAY) Reports Initiation of Phase 2b Study of Seladelpar in Patients with Non-Alcoholic SteatohepatitisCymaBay Therapeutics (CBAY) Reports Initiation of Phase 2b Study of Seladelpar in Patients with Non-Alcoholic Steatohepatitis
www.streetinsider.com - May 8 at 3:55 PM
CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic ...CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic ...
globenewswire.com - May 8 at 10:01 AM
BRIEF-CymaBay Initiates Phase 2B Study Of Seladelpar In Patients With Non-Alcoholic SteatohepatitisBRIEF-CymaBay Initiates Phase 2B Study Of Seladelpar In Patients With Non-Alcoholic Steatohepatitis
www.reuters.com - May 8 at 10:01 AM
CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic SteatohepatitisCymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic Steatohepatitis
finance.yahoo.com - May 8 at 10:01 AM
$5.00 Million in Sales Expected for CymaBay Therapeutics (CBAY) This Quarter$5.00 Million in Sales Expected for CymaBay Therapeutics (CBAY) This Quarter
www.americanbankingnews.com - May 4 at 3:02 AM
CymaBay Therapeutics (CBAY) Rating Increased to Strong-Buy at ValuEngineCymaBay Therapeutics (CBAY) Rating Increased to Strong-Buy at ValuEngine
www.americanbankingnews.com - May 3 at 10:04 PM
 Brokerages Anticipate CymaBay Therapeutics (CBAY) Will Announce Earnings of -$0.14 Per Share Brokerages Anticipate CymaBay Therapeutics (CBAY) Will Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - May 2 at 1:12 PM
CymaBay Therapeutics (CBAY) Set to Announce Earnings on WednesdayCymaBay Therapeutics (CBAY) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - May 2 at 3:32 AM
CymaBay to Report First Quarter 2018 Financial Results on Tuesday, May 8CymaBay to Report First Quarter 2018 Financial Results on Tuesday, May 8
finance.yahoo.com - May 1 at 10:03 AM
CymaBay Therapeutics (CBAY) Receives Consensus Recommendation of "Buy" from AnalystsCymaBay Therapeutics (CBAY) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 21 at 1:36 AM
Analysts’ Ratings for Achaogen and Peers in April 2018Analysts’ Ratings for Achaogen and Peers in April 2018
finance.yahoo.com - April 18 at 10:17 AM
FY2021 Earnings Estimate for CymaBay Therapeutics Issued By Oppenheimer (CBAY)FY2021 Earnings Estimate for CymaBay Therapeutics Issued By Oppenheimer (CBAY)
www.americanbankingnews.com - April 18 at 8:56 AM
CymaBay Therapeutics (CBAY) Given New $12.00 Price Target at HC WainwrightCymaBay Therapeutics (CBAY) Given New $12.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 17 at 11:28 PM
CymaBay Therapeutics (CBAY) PT Set at $7.00 by Piper JaffrayCymaBay Therapeutics (CBAY) PT Set at $7.00 by Piper Jaffray
www.americanbankingnews.com - April 17 at 10:21 PM
CymaBay Therapeutics (CBAY) Given a $20.00 Price Target at OppenheimerCymaBay Therapeutics (CBAY) Given a $20.00 Price Target at Oppenheimer
www.americanbankingnews.com - April 17 at 11:37 AM
Exploring CymaBay’s Other Promising Product CandidatesExploring CymaBay’s Other Promising Product Candidates
finance.yahoo.com - April 17 at 10:13 AM
How Has CymaBay Therapeutics Performed Financially?How Has CymaBay Therapeutics Performed Financially?
finance.yahoo.com - April 17 at 10:13 AM
 Brokerages Anticipate CymaBay Therapeutics (CBAY) Will Post Quarterly Sales of $5.00 Million Brokerages Anticipate CymaBay Therapeutics (CBAY) Will Post Quarterly Sales of $5.00 Million
www.americanbankingnews.com - April 17 at 3:29 AM
CymaBay Therapeutics (CBAY) Earns Overweight Rating from Piper JaffrayCymaBay Therapeutics (CBAY) Earns Overweight Rating from Piper Jaffray
www.americanbankingnews.com - April 16 at 2:25 PM
CymaBay Therapeutics (CBAY) Expected to Earn Q1 2018 Earnings of ($0.07) Per ShareCymaBay Therapeutics (CBAY) Expected to Earn Q1 2018 Earnings of ($0.07) Per Share
www.americanbankingnews.com - April 16 at 1:36 AM
Zacks: Brokerages Expect CymaBay Therapeutics (CBAY) to Announce -$0.14 EPSZacks: Brokerages Expect CymaBay Therapeutics (CBAY) to Announce -$0.14 EPS
www.americanbankingnews.com - April 15 at 1:23 PM
BidaskClub Lowers CymaBay Therapeutics (CBAY) to BuyBidaskClub Lowers CymaBay Therapeutics (CBAY) to Buy
www.americanbankingnews.com - April 13 at 4:55 PM
CymaBay Therapeutics (CBAY) PT Raised to $21.00 at HC WainwrightCymaBay Therapeutics (CBAY) PT Raised to $21.00 at HC Wainwright
www.americanbankingnews.com - April 13 at 10:37 AM
Oppenheimer Reiterates $18.00 Price Target for CymaBay Therapeutics (CBAY)Oppenheimer Reiterates $18.00 Price Target for CymaBay Therapeutics (CBAY)
www.americanbankingnews.com - April 12 at 10:19 AM
Could This Tiny Biotech Rout Intercept In Liver Disease Drugs?Could This Tiny Biotech Rout Intercept In Liver Disease Drugs?
finance.yahoo.com - April 11 at 3:56 PM
CymaBay Therapeutics (CBAY) Stock Rating Reaffirmed by Leerink SwannCymaBay Therapeutics (CBAY) Stock Rating Reaffirmed by Leerink Swann
www.americanbankingnews.com - April 11 at 11:30 AM
CymaBay Announces Positive New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2018CymaBay Announces Positive New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2018
finance.yahoo.com - April 11 at 10:51 AM
5 Small-Cap Stocks With Explosive Upside Potential5 Small-Cap Stocks With Explosive Upside Potential
finance.yahoo.com - April 9 at 10:33 AM
CymaBay Therapeutics (CBAY) Given a $15.00 Price Target at OppenheimerCymaBay Therapeutics (CBAY) Given a $15.00 Price Target at Oppenheimer
www.americanbankingnews.com - April 4 at 3:32 PM
CymaBay Therapeutics (CBAY) Lifted to Buy at ValuEngineCymaBay Therapeutics (CBAY) Lifted to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 6:26 PM
Zacks: Analysts Expect CymaBay Therapeutics Inc (CBAY) Will Post Quarterly Sales of $5.00 MillionZacks: Analysts Expect CymaBay Therapeutics Inc (CBAY) Will Post Quarterly Sales of $5.00 Million
www.americanbankingnews.com - March 31 at 2:28 AM
Q2 2018 Earnings Estimate for CymaBay Therapeutics Inc Issued By Leerink Swann (CBAY)Q2 2018 Earnings Estimate for CymaBay Therapeutics Inc Issued By Leerink Swann (CBAY)
www.americanbankingnews.com - March 30 at 7:00 AM
-$0.12 Earnings Per Share Expected for CymaBay Therapeutics Inc (CBAY) This Quarter-$0.12 Earnings Per Share Expected for CymaBay Therapeutics Inc (CBAY) This Quarter
www.americanbankingnews.com - March 29 at 5:22 PM
Oppenheimer Analysts Give CymaBay Therapeutics (CBAY) a $15.00 Price TargetOppenheimer Analysts Give CymaBay Therapeutics (CBAY) a $15.00 Price Target
www.americanbankingnews.com - March 28 at 8:42 PM
CymaBay Therapeutics (CBAY) Receives New Coverage from Analysts at HC WainwrightCymaBay Therapeutics (CBAY) Receives New Coverage from Analysts at HC Wainwright
www.americanbankingnews.com - March 28 at 2:04 PM
CymaBay Therapeutics Inc (CBAY) Given Average Recommendation of "Buy" by AnalystsCymaBay Therapeutics Inc (CBAY) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 27 at 1:39 AM
CymaBay Therapeutics (CBAY) Upgraded by ValuEngine to "Hold"CymaBay Therapeutics (CBAY) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - March 25 at 8:10 PM

SEC Filings

CymaBay Therapeutics (NASDAQ:CBAY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CymaBay Therapeutics (NASDAQ:CBAY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CymaBay Therapeutics (NASDAQ CBAY) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.